DK1461049T3 - Anvendelse af sulfaterede glycosaminoglykoner til etablering af effektiv födsel hos kvinder - Google Patents

Anvendelse af sulfaterede glycosaminoglykoner til etablering af effektiv födsel hos kvinder

Info

Publication number
DK1461049T3
DK1461049T3 DK03700633T DK03700633T DK1461049T3 DK 1461049 T3 DK1461049 T3 DK 1461049T3 DK 03700633 T DK03700633 T DK 03700633T DK 03700633 T DK03700633 T DK 03700633T DK 1461049 T3 DK1461049 T3 DK 1461049T3
Authority
DK
Denmark
Prior art keywords
pregnant woman
labor
myometrium
cervix
molecular weight
Prior art date
Application number
DK03700633T
Other languages
Danish (da)
English (en)
Inventor
Gunvor Ekman-Ordeberg
Anders Malmstroem
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilafor Ab filed Critical Dilafor Ab
Application granted granted Critical
Publication of DK1461049T3 publication Critical patent/DK1461049T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03700633T 2002-01-02 2003-01-02 Anvendelse af sulfaterede glycosaminoglykoner til etablering af effektiv födsel hos kvinder DK1461049T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200005A SE521676C2 (sv) 2002-01-02 2002-01-02 Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
PCT/SE2003/000004 WO2003055499A1 (en) 2002-01-02 2003-01-02 Use of sulfated glycosaminoglycans for establishing effective labor in women

Publications (1)

Publication Number Publication Date
DK1461049T3 true DK1461049T3 (da) 2008-09-15

Family

ID=20286575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03700633T DK1461049T3 (da) 2002-01-02 2003-01-02 Anvendelse af sulfaterede glycosaminoglykoner til etablering af effektiv födsel hos kvinder

Country Status (21)

Country Link
US (3) US7407945B2 (pl)
EP (1) EP1461049B1 (pl)
JP (1) JP4434741B2 (pl)
KR (1) KR100958691B1 (pl)
CN (1) CN100341518C (pl)
AT (1) ATE395067T1 (pl)
AU (1) AU2003201787B2 (pl)
CA (1) CA2472093C (pl)
CY (1) CY1108260T1 (pl)
DE (1) DE60320931D1 (pl)
DK (1) DK1461049T3 (pl)
ES (1) ES2306852T3 (pl)
IL (2) IL162664A0 (pl)
NO (1) NO332702B1 (pl)
NZ (1) NZ533856A (pl)
PL (1) PL206458B1 (pl)
PT (1) PT1461049E (pl)
SE (1) SE521676C2 (pl)
SI (1) SI1461049T1 (pl)
WO (1) WO2003055499A1 (pl)
ZA (1) ZA200405015B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
RU2617764C2 (ru) * 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
AU2013240597A1 (en) * 2012-03-26 2014-10-16 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
MX2014011451A (es) * 2012-03-26 2014-11-10 Dilafor Ab Procedimiento de tratamiento de la interrupcion del parto.
RU2014149230A (ru) * 2012-05-08 2016-06-27 Дилафор Аб Лечение послеродового кровотечения (прк)
EP2879697A4 (en) 2012-08-03 2016-01-20 Lfb Usa Inc USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE
WO2021165240A1 (en) 2020-02-17 2021-08-26 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
EP4518872A1 (en) 2022-05-03 2025-03-12 Dilafor AB New medical use of tafoxiparin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
EP0209924A1 (en) * 1985-07-12 1987-01-28 Akzo N.V. New anti-trombosis agent based on glycosaminoglycan, process for its preparation, and pharmaceutical compositions
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
US6020322A (en) * 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
US6025335A (en) * 1995-09-21 2000-02-15 Lipitek International, Inc. L-Nucleoside Dimer Compounds and therapeutic uses
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
AU4572797A (en) * 1996-10-15 1998-05-11 Toray Industries, Inc. Cervical canal maturing agent
JP4412756B2 (ja) 1998-02-26 2010-02-10 生化学工業株式会社 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
CA2335617C (en) * 1998-06-24 2009-12-15 Novirio Pharmaceuticals Limited Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
JP2000309544A (ja) * 1999-02-25 2000-11-07 Seikagaku Kogyo Co Ltd 早産または流産防止剤および子宮頚管熟化抑制剤ならびにヒアルロニダーゼの阻害剤
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet

Also Published As

Publication number Publication date
AU2003201787A1 (en) 2003-07-15
NO332702B1 (no) 2012-12-10
CA2472093C (en) 2011-02-22
ZA200405015B (en) 2005-08-31
JP4434741B2 (ja) 2010-03-17
WO2003055499A1 (en) 2003-07-10
KR20040075917A (ko) 2004-08-30
US20050075314A1 (en) 2005-04-07
JP2005513148A (ja) 2005-05-12
PL370428A1 (pl) 2005-05-30
US8207145B2 (en) 2012-06-26
SE521676C2 (sv) 2003-11-25
CN1612741A (zh) 2005-05-04
NO20043190L (no) 2004-07-26
SE0200005L (sv) 2003-07-03
US7407945B2 (en) 2008-08-05
PL206458B1 (pl) 2010-08-31
CN100341518C (zh) 2007-10-10
US20120225843A1 (en) 2012-09-06
HK1076389A1 (en) 2006-01-20
PT1461049E (pt) 2008-08-22
IL162664A0 (en) 2005-11-20
SI1461049T1 (sl) 2008-12-31
IL162664A (en) 2009-06-15
SE0200005D0 (sv) 2002-01-02
EP1461049B1 (en) 2008-05-14
US8524688B2 (en) 2013-09-03
AU2003201787B2 (en) 2008-02-28
CA2472093A1 (en) 2003-07-10
KR100958691B1 (ko) 2010-05-18
DE60320931D1 (de) 2008-06-26
US20080269165A1 (en) 2008-10-30
ES2306852T3 (es) 2008-11-16
ATE395067T1 (de) 2008-05-15
EP1461049A1 (en) 2004-09-29
NZ533856A (en) 2004-12-24
CY1108260T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
DK1461049T3 (da) Anvendelse af sulfaterede glycosaminoglykoner til etablering af effektiv födsel hos kvinder
Lavery et al. The efficacy and safety of Grafix® for the treatment of chronic diabetic foot ulcers: results of a multi‐centre, controlled, randomised, blinded, clinical trial
Abbade et al. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment
Zykova et al. Macrophage stimulating agent soluble yeast β‐1, 3/1, 6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase II study
Clagett et al. Prevention of venous thromboembolism
Zhou et al. Role of different negative pressure values in the process of infected wounds treated by vacuum‐assisted closure: an experimental study
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE602004018944D1 (de) Verwendung von abführmittel zur behandlung des reizdarmsyndroms
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
MX2007011002A (es) Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica.
Caprini et al. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
WO2005060960A3 (en) Use of histamine to treat bone disease
BRPI0414887A (pt) métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
RU2004108122A (ru) Сверхразветвленный амилопектин для применения в способах хирургического или терапевтического лечения млекопитающих, или в диагностических методах, особенно для применения в качестве объемного плазмозаменителя
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
Bergqvist Update on in hospital venous thromboembolism prophylaxis
US11571494B2 (en) Method for treating subjects suffering from chronic ulcers
RU2014149230A (ru) Лечение послеродового кровотечения (прк)
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
Rockson Lymphedema
ATE324905T1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall
Manjra Venous leg ulcers: a literature review
Ahmed et al. The Use of Hyaluronic Acid in Reducing Postoperative Complications in Minor Oral Surgery: A Review